Biogen, BioAge and PTC Present Novel MoAs in Neurodegenerative Diseases

Therapies in development for neurodegenerative diseases are looking beyond Alzheimer’s and Parkinson’s with novel mechanisms of action targeting newer pathways.

BioAge Labs, PTC Therapeutics, Biogen and others highlighted these approaches at the Cambridge Innovation Institute's recent Discovery on Target meeting.